Health

BOSTON, July 01, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases...

SAN FRANCISCO, June 28, 2022 /PRNewswire/ -- Human Reproduction journal has published the ground-breaking results of an international clinical study, where a novel AI algorithm called Life Whisperer Genetics was...

CAMBRIDGE, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted stock option awards to...

NEW YORK, June 29, 2022 /PRNewswire/ -- M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement with GenFleet...

Four leading experts in respiratory allergy spotlight the impact of respiratory allergy in children, in an ALK-sponsored symposium at the EAACI CongressThe growing availability of evidence-based allergy immunotherapy treatments for...

LAS VEGAS, June 29, 2022 /PRNewswire/ -- Insurance providers are now able to evaluate customer health risks in real-time using a revolutionary contactless wellness and vital sign monitoring solution from...

LOS ANGELES, July 01, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—In recent days, Enochian BioSciences (the Company) has conducted a rigorous internal review of scientific data to give partners and investors...

In a unique effort to augment support for the selfless services of medical practitioners in the country and to support them to serve patients better, an awareness-cum-people-connect campaign was...

- Second large-scale trial shows greater reduction in tinnitus symptom severity using bimodal neuromodulation device, Lenire® - 91% of treatment compliant participants experienced improvement in tinnitus symptoms that sustained 12...

RESEARCH TRIANGLE PARK, N.C., July 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 40,400...